Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025)
Evotec SE (EVO) posted Net Income towards Common Stockholders of -$120.4 million for Q4 2025, down 240274.03% sequentially from -$50074.1 in Q3 2025, and up 42.5% YoY from -$84.5 million in Q4 2024.
Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025) Analysis & Trends
Evotec SE has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$120.4 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 42.5% year-over-year to -$120.4 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$120.4 million (up 42.49% YoY) and the FY2025 annual result came in at -$120.5 million, up 42.49% from the prior year.
- Net Income towards Common Stockholders declined to -$120.4 million in Q4 2025 per EVO's latest filing, from -$50074.1 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $246.3 million in Q4 2021 and troughed at -$209.3 million in Q4 2024.
- A 5-year average of -$23.5 million and a median of -$29810.4 in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2021 and 2024: Net Income towards Common Stockholders jumped 9714.16% in 2021, then tumbled 240.15% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at $246.3 million in 2021, then slumped by 172.84% to -$179.4 million in 2022, then soared by 49.69% to -$90.2 million in 2023, then plunged by 131.96% to -$209.3 million in 2024, then surged by 42.5% to -$120.4 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$120.4 million, -$50074.1, and -$209.3 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evotec SE | 692.56 Mn | 692.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.37 Mn |
| Sep 30, 2025 | -50,074.14 |
| Dec 31, 2024 | -209.31 Mn |
| Sep 30, 2024 | -59,430.15 |
| Dec 31, 2023 | -90.24 Mn |
| Sep 30, 2023 | 42,406.04 |
| Jun 30, 2023 | -13,888.14 |
| Dec 31, 2022 | -179.36 Mn |
| Sep 30, 2022 | 47,666.17 |
| Jun 30, 2022 | -29,810.36 |
| Mar 31, 2022 | -82,202.26 |
| Dec 31, 2021 | 246.25 Mn |
| Sep 30, 2021 | 158,344.09 |
| Jun 30, 2021 | 72,274.35 |
| Mar 31, 2021 | 63,571.06 |
| Dec 31, 2020 | 7.48 Mn |
| Sep 30, 2020 | -1,646.99 |
| Dec 31, 2019 | 42.23 Mn |
| Sep 30, 2010 | 1,385.54 |
| Jun 30, 2010 | 1,510.68 |